Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.42 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.42 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695049 | 1.00 | FSCN1 (0.52) | FSCN1CNR1PTGER4SLC2A1TP53 | |
| SCHEMBL18532108 | 0.92 | FSCN1 (0.52) | FSCN1CNR1PTGER4SLC2A1CPT1A | |
| SCHEMBL17039039 | 0.92 | FSCN1 (0.52) | FSCN1PTGER4TP53MEN1KMT2A | |
| SCHEMBL30695016 | 0.92 | FSCN1 (0.52) | FSCN1PTGER4TP53MEN1KMT2A | |
| SCHEMBL17038741 | 0.91 | FSCN1 (0.51) | FSCN1PTGER4TP53KMT2AALDH1A1 | |
| SCHEMBL30501118 | 0.91 | FSCN1 (0.51) | FSCN1PTGER4TP53KMT2AALDH1A1 | |
| SCHEMBL17038830 | 0.89 | FSCN1 (0.67) | FSCN1PTGER4SLC2A1CPT1APTGDR2 | |
| SCHEMBL30501138 | 0.89 | FSCN1 (0.67) | FSCN1PTGER4SLC2A1CPT1APTGDR2 | |
| SCHEMBL21661800 | 0.88 | FSCN1 (0.44) | FSCN1CNR1PTGER4SLC2A1TP53 | |
| SCHEMBL17038801 | 0.87 | FSCN1 (0.48) | FSCN1SLC2A1POLBSLC2A2SLC2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-9850243-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885CNR1 4375/4885PTGER4 4107/4885 |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885CNR1 4375/4885PTGER4 4107/4885 |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885CNR1 4375/4885PTGER4 4107/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | FSCN1 1/4885CNR1 4375/4885PTGER4 4107/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | FSCN1 1017/4885CNR1 4017/4885PTGER4 4560/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885CNR1 4375/4885PTGER4 4107/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | FSCN1 1017/4885CNR1 4017/4885PTGER4 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.